Mutation in a highly conserved glycine residue in strand 5B of plasminogen activator inhibitor 1 causes polymerisation

Summary

Serpinopathy is characterised as abnormal accumulation of serine protease inhibitors (SERPINs) in cells and results in clinical symptoms owing to lack of SERPIN function or excessive accumulation of abnormal SERPIN. We recently identified a patient with functional deficiency of plasminogen activator inhibitor-1 (PAI-1), a member of the SERPIN superfamily. The patient exhibited life-threatening bleeding tendencies, which have also been observed in patients with a complete deficiency in PAI-1. Sequence analysis revealed a homozygous singlenucleotide substitution from guanine to cytosine at exon 9, which changed amino acid residue 397 from glycine to arginine (c.1189G>C; p.Gly397Arg). This glycine was located in strand 5B and was well conserved in other serpins. The mutant PAI-1 was polymerised in the cells, interfering with PAI-1 secretion. The corresponding mutations in SERPINC1 (anti-thrombin III) at position 456 (Gly456Arg) and SERPINI1 (neuroserpin) at position 392 (Gly392Glu) caused an anti-thrombin deficiency and severe dementia due to intracellular retention of the polymers. Glycine is the smallest amino acid, and these mutated amino acids were larger and charged. To determine which factors were important, further mutagenesis of PAI-1 was performed. Although the G397A, C, I, L, S, T, and V were secreted, the G397D, E, F, H, K, M, N, P, Q, W, and Y were not secreted. The results revealed that the size was likely triggered by the polymerisation of SEPRINs at this position. Structural analyses of this mutated PAI-1 would be useful to develop a novel PAI-1 inhibitor, which may be applicable in the context of several pathological states.

Keywords

Plasminogen activator inhibitor 1 - SERPINE1 - mutation - bleeding disorder - serpinopathy

• References

• 1 Sharp HL, Bridges RA, Krivit W. et al. Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder. J Lab Clin Med 1969; 73: 934-939.
• 2 Wewers MD, Casolaro MA, Sellers SE. et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316: 1055-1062.
• 3 Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989; 09: 87-115.
• 4 Iwaki T, Urano T, Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol 2012; 157: 291-298.
• 5 Iwaki T, Tanaka A, Miyawaki Y. et al. Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. J Thromb Haemost 2011; 09: 1200-1206.
• 6 Iwaki T, Nagahashi K, Kobayashi T. et al. The first report of uncontrollable subchorionic and retroplacental haemorrhage inducing preterm labour in complete PAI-1 deficiency in a human. Thromb Res 2012; 129: e161-163.
• 7 Fay WP, Shapiro AD, Shih JL. et al. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327: 1729-1733.
• 8 Urano T, Sumiyoshi K, Pietraszek MH. et al. PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA. Thromb Haemost 1991; 66: 474-478.
• 9 Nagahashi K, Umemura K, Kanayama N. et al. Fusion of fluorescent protein to puromycin N-acetyltransferase is useful in Drosophila Schneider S2 cells expressing heterologous proteins. Cytotechnology 2013; 65: 173-178.
• 10 Jankun J, Yang J, Zheng H. et al. Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure. Int J Mol Med 2012; 29: 61-64.
• 11 Elliott PR, Pei XY, Dafforn TR. et al. Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci 2000; 09: 1274-1281.
• 12 Li W, Adams TE, Kjellberg M. et al. Structure of native protein C inhibitor provides insight into its multiple functions. J Biol Chem 2007; 282: 13759-13768.
• 13 Baglin TP, Carrell RW, Church FC. et al. Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc Natl Acad Sci USA 2002; 99: 11079-11084.
• 14 Beinrohr L, Harmat V, Dobo J. et al. C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease. J Biol Chem 2007; 282: 21100-21109.
• 15 Takehara S, Onda M, Zhang J. et al. The 2.1-A crystal structure of native neuroserpin reveals unique structural elements that contribute to conformational instability. J Mol Biol 2009; 388: 11-20.
• 16 Urano T, Castellino FJ, Ihara H. et al. Activated protein C attenuates coagulation-associated over-expression of fibrinolytic activity by suppressing the thrombin-dependent inactivation of PAI-1. J Thromb Haemost 2003; 01: 2615-2620.
• 17 Ryu SE, Choi HJ, Kwon KS. et al. The native strains in the hydrophobic core and flexible reactive loop of a serine protease inhibitor: crystal structure of an uncleaved alpha1-antitrypsin at 2.7 A. Structure 1996; 04: 1181-1192.
• 18 Heiman M, Gupta S, Shapiro AD. The obstetric, gynaecological and fertility implications of homozygous PAI-1 deficiency: single-centre experience. Haemophilia 2014; 20: 407-412.
• 19 Carmeliet P, Kieckens L, Schoonjans L. et al. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterisation. J Clin Invest 1993; 92: 2746-2755.
• 20 Davis RL, Shrimpton AE, Holohan PD. et al. Familial dementia caused by polymerisation of mutant neuroserpin. Nature 1999; 401: 376-379.
• 21 Aulak KS, Eldering E, Hack CE. et al. A hinge region mutation in C1-inhibitor (Ala436-->Thr) results in nonsubstrate-like behavior and in polymerisation of the molecule. J Biol Chem 1993; 268: 18088-18094.
• 22 Corral J, Huntington JA, Gonzalez-Conejero R. et al. Mutations in the shutter region of antithrombin result in formation of disulfide-linked dimers and severe venous thrombosis. J Thromb Haemost 2004; 02: 931-939.
• 23 Carrell RW, Stein PE. The biostructural pathology of the serpins: critical function of sheet opening mechanism. Biol Chem Hoppe Seyler 1996; 377: 1-17.
• 24 Lomas DA, Evans DL, Finch JT. et al. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992; 357: 605-607.
• 25 Zhou A, Faint R, Charlton P. et al. Polymerisation of plasminogen activator inhibitor-1. J Biol Chem 2001; 276: 9115-9122.
• 26 Yamasaki M, Li W, Johnson DJ. et al. Crystal structure of a stable dimer reveals the molecular basis of serpin polymerisation. Nature 2008; 455: 1255-1258.
• 27 Jochmans K, Lissens W, Vervoort R. et al. Antithrombin-Gly 424 Arg: a novel point mutation responsible for type 1 antithrombin deficiency and neonatal thrombosis. Blood 1994; 83: 146-151.
• 28 Davis RL, Shrimpton AE, Carrell RW. et al. Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet 2002; 359: 2242-2247.
• 29 Soeda S, Koyanagi S, Kuramoto Y. et al. Anti-apoptotic roles of plasminogen activator inhibitor-1 as a neurotrophic factor in the central nervous system. Thromb Haemost 2008; 100: 1014-1020.
• 30 Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
• 31 Meltzer ME, Doggen CJ, de Groot PG. et al. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost 2009; 35: 468-477.
• 32 Binder BR, Mihaly J. The plasminogen activator inhibitor “paradox” in cancer. Immunol Lett 2008; 118: 116-124.